{"schema_version":"secwatch.filing_event.v1","accession":"0002036042-25-000014","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.755755+00:00","generated_at":"2026-05-22T00:46:02.419102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sionna Therapeutics Q1 net loss $16.5M; cash $354.7M; Phase 1 dosing complete for two NBD1 stabilizers","bullets":["Net loss of $16.5M for Q1 2025, up from $11.8M in Q1 2024; R&D expenses $13.7M vs $10.2M.","Cash and cash equivalents $354.7M as of March 31, 2025, including $199.6M net IPO proceeds; runway into 2028.","Phase 1 dosing completed for SION-719 and SION-451; topline data expected in Q2 2025.","Phase 2a POC trial and at least one dual combination MAD trial on track for H2 2025; topline data mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002036042-25-000014","json":"https://secwatch.observer/filing/0002036042-25-000014.json","markdown":"https://secwatch.observer/filing/0002036042-25-000014.md","text":"https://secwatch.observer/filing/0002036042-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000014/0002036042-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000014/sion-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:46:02.419102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}